Friday, 9 October 2026
Immediate adrenaline in anaphylaxis, Victorian pharmacy MHT resupply, Medical abortion pharmacy access expands
- 01
Updated anaphylaxis guidance prioritises immediate adrenaline and refractory pathways
Updated ASCIA guidance directs health professionals to give adrenaline without delay when anaphylaxis is suspected, including when acute hypotension or respiratory impairment occurs without typical skin features. For patients with known asthma and allergy who develop sudden breathing difficulty after possible allergen exposure, adrenaline should precede asthma reliever medication; bronchodilators must not replace it. The initial pathway advises repeating adrenaline after five minutes if response is absent or inadequate, while persistent respiratory or cardiovascular symptoms after two doses constitute refractory anaphylaxis and require early expert help, adrenaline infusion, fluid resuscitation and critical care support. The guidance also says patients should not stand or walk during anaphylaxis and should be observed for at least four hours after their last adrenaline dose. It includes all adrenaline devices approved in Australia and New Zealand, including intranasal products, and recommends specialist referral after anaphylaxis.
- 02
Victorian pharmacists can now provide one-month MHT resupply
Participating Victorian pharmacists can now dispense a one-month resupply of menopausal hormone therapy (MHT), while qualified pharmacists can also treat gastro-oesophageal reflux disease under the expanded Chemist Care Now program. MHT resupply is limited to women aged 45–59, or those aged at least 30 with confirmed surgical menopause, who have seen their GP within 12 months and used the same therapy for at least six months. Pharmacists must complete specialised training, conduct a thorough private consultation, outline risks and refer patients requiring further care to a medical practitioner. RACGP Victoria Deputy Co-Chair Dr Aadhil Aziz raised concerns that bypassing repeat-prescription visits could compromise follow-up and allow contraindications, thyroid disorders, screening, immunisations or cancers to be missed. The expansion comes amid continuing MHT supply disruptions, with the TGA extending its Serious Scarcity Substitution Instrument for affected products until 28 February 2027.
via RACGP newsGP
- 03
MS-2 Step pharmacy access expanded after prescribing reforms
The number and geographic distribution of Australian pharmacies ordering MS-2 Step increased immediately and sustainably after prescribing restrictions were removed in 2023. The number of pharmacies that had ever ordered the medicine rose from 2228 before August 2023 to 4107 after the changes. The TGA removed mandatory training and three-yearly registration requirements for GPs, allowed pharmacies to stock and dispense MS-2 Step, and enabled appropriately qualified health professionals, including nurse practitioners, to prescribe it. The study analysed monthly pharmacy orders using sales data from Australia’s sole mifepristone distributor across the 24 months before and after the regulatory change. Researchers said the expansion improved geographic access to medical abortion, although study co-author Professor Danielle Mazza said barriers to GP prescribing remain.
via RACGP newsGP · also covered by The Medical Republic
- 04
MBS review begins on allied health specialist referrals
The Department of Health, Disability and Ageing has begun reviewing direct referrals from allied health professionals to non-GP specialists under recommendation 12 of the 2024 scope of practice review. The proposal would create pathways to specified specialist MBS items when referrals are made within the health professional’s scope of practice and accompanied by timely notification to the patient’s usual GP. Potential pathways include physiotherapists referring to orthopaedic surgeons, psychologists to psychiatrists and diabetes educators to endocrinologists. Current rules allow allied health professionals to write these referrals, but patients generally cannot receive an MBS rebate for the resulting consultation. The review is expected to take about 18 months and include targeted and public consultations.
- 05
One in six Australians used AI for mental health support
One in six Australian adults used generative AI for mental health advice or support, making it the third most common support source in a Beyond Blue survey of more than 5000 adults. Seven per cent of respondents used AI instead of professional support, while 6% used it before deciding whether to seek professional care and 5% used both. Despite its convenience and low cost, 86% reported concerns about AI’s accuracy, reliability, empathy and potential to provide harmful information. Overall, 41% sought mental health support in 2026, up from 37% in 2022, while the proportion delaying or going without support fell from 22% in 2024 to 19%. Separately, the AMA called for integrated, medically led and long-term care for people with severe and enduring mental illness, arguing that fragmented, crisis-driven services lacked continuity.
- 06
New interpreter resource covers safe use and consultation billing
The RACGP and the National Accreditation Authority for Translators and Interpreters have launched a resource on using interpreters in general practice. It covers when and how to engage an interpreter and how to work with interpreters effectively. The guidance also addresses risks associated with informal interpreting, bilingual staff and AI-assisted communication, as well as NAATI certification and quality assurance. It includes information on billing for interpreted consultations and is available as a full resource and quick guide.
via RACGP newsGP
MDDR is a news digest for medical professionals. It is not medical advice and should not be relied on for clinical decision-making.